Posted by Michael Wonder on 30 Mar 2017
pERC publishes final outcome for Amgen's Kyprolis
30 March 2017 - The outcome relates to the use of carfilzomib in combination with dexamethasone by patients with relapsed multiple myeloma.
The pERC has recommended the reimbursement of carfilzomib when used in combination with dexamethasone by patients with relapsed multiple myeloma with good performance status who have received one to three prior treatments.
Consistent with many recent positive pERC outcomes, the recommendation has a condition; cost-effectiveness must be improved to an acceptable level.
